<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042258</url>
  </required_header>
  <id_info>
    <org_study_id>2021-4161</org_study_id>
    <nct_id>NCT05042258</nct_id>
  </id_info>
  <brief_title>Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis</brief_title>
  <official_title>Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, prospective, Open label study of sleep, pruritus and circadian function&#xD;
      pre/post 12-weeks of dupilumab treatment in children 6-17 years old&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will complete two overnight sleep studies, before and after using dupilumab for 12&#xD;
      weeks, to assess the effect of dupilumab on sleep disturbance in eczema patients. These&#xD;
      overnight visits will include PSG, blood draws, skin sensors, urine collection, tape&#xD;
      stripping, and photography. Subjects will be given dupilumab to use for 12 weeks at home&#xD;
      before returning for the second sleep study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PROMIS (Patient Reported Outcome Measurement Information System) parent-proxy score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement from baseline in PROMIS Parent-Proxy sleep disturbance score (short format 8-item) after 12 weeks post dupilumab initiation. The minimum value is &quot;Never&quot; and the maximum value is &quot;Always&quot;. Higher scores mean worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PROMIS patient score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement from baseline in PROMIS Patient-reported sleep disturbance score (short format 8-item) after 12 weeks post dupilumab initiation (in children ≥ 8 years old). The minimum value is &quot;Never&quot; and the maximum value is &quot;Always&quot;. Higher scores mean worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wake After Sleep Onset</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of patients achieving clinically significant improvement in minutes of Wake After Sleep Onset from baseline to Week 12 on inpatient polysomnography (PSG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency in the Clinical Sleep Lab</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in percent Sleep Efficiency on PSG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Onset Latency in the Clinical Sleep Lab</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in Sleep Onset Latency in minutes on PSG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time in the Clinical Sleep Lab</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in Total Sleep Time in minutes on PSG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periodic Limb Movement Frequency in the Clinical Sleep Lab</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in periodic limb movement frequency on PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Wave Sleep Time in the Clinical Sleep Lab</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in % of time spent in slow wave sleep (generally stage 3 sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REM (Rapid Eye Movement) Sleep Time in the Clinical Sleep Lab</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in % of time spent in REM sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake After Sleep Onset (WASO) at Home</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in minutes of WASO averaged over 1-week of outpatient actigraphy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency at Home</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in percent Sleep Efficiency on actigraphy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Onset Latency at Home</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in Sleep Onset Latency in minutes on actigraphy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time at Home</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in Total Sleep Time in minutes on actigraphy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of weeks it takes to achieve 5-point improvement from baseline in patient/parent-proxy reported sleep disturbance (assessed by weekly PROMIS sleep disturbance measures).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Sleep Assessments</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline in weekly PROMIS sleep assessments at Weeks 1-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Itch Severity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to Week 12 in PROMIS parent-proxy and patient-reported itch severity Numeric Rating Scale (NRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch NRS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline in weekly Itch NRS at Weeks 1-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Itch Intensity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to Week 12 in PROMIS parent-proxy and patient-reported itch intensity and impact assessment (PIQ-C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scratch</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to Week 12 in total minutes spent scratching during polysomnography (PSG).&#xD;
Percent change from baseline to Week 12 in number of scratching bouts during polysomnography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to Week 12 in Eczema Area and Severity Index (EASI) Score.&#xD;
EASI score objectively measures disease severity. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with higher scores reflecting worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema Area and Severity Index 75 (EASI-75)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of patients with 75% or more improvement from baseline in Eczema Area and Severity Index (EASI-75)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to Week 12 in Patient Oriented Eczema Measure (POEM) by parent-proxy and children report (in patients ≥8yo).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Dermatology Life Quality Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in Children's Dermatology Life Quality Index (CDLQI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pediatric Profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in PROMIS Pediatric Profile measure (general QOL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inattention Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in Inattention Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of Skin Barrier Hydration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in the amplitude of skin barrier hydration during 24 hours of monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Skin Temperature</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in the peripheral skin temperature during 24 hours of monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of Melatonin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in the amplitude of melatonin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transepidermal Water Loss</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in the Transepidermal Water Loss (TEWL) during hourly monitoring while patients are awake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+CLA+ and CD8+CLA+ Transcriptome Changes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quantify CD4+CLA+ and CD8+CLA+ transcriptome changes from baseline to Week 12 (blood transcriptome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin-Homing T-Cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the presence of changes noted in skin-homing T-cells from baseline to Week 12 in the epidermal transcriptome (skin transcriptome).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Sleep Disturbance</condition>
  <arm_group>
    <arm_group_label>Dupilumab administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dupilumab administered in weight based dosage for 12 weeks. The drug will be administered once a week during this time through a subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>12 week dupilumab administration</description>
    <arm_group_label>Dupilumab administration</arm_group_label>
    <other_name>Dupixent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants, 6-17 years old at time of enrollment.&#xD;
&#xD;
          -  Moderate to severe chronic AD inadequately controlled by topical treatment, diagnosed&#xD;
             according to Hanifin and Rajka criteria by a pediatric dermatologist or allergist.&#xD;
&#xD;
          -  AD severity will be determined at baseline with Validated Investigator Global&#xD;
             Assessment (vIGA) score of moderate (3) or severe (4).&#xD;
&#xD;
          -  Patient assessed or parent-proxy (under 8 years old) PROMIS sleep disturbance T-score&#xD;
             ≥60.&#xD;
&#xD;
          -  Willing and able to comply with visits and study-related procedures.&#xD;
&#xD;
          -  On stable regimens (consistent use 14 days before Day 1 of study enrollment) of&#xD;
             inhaled corticosteroids, topical steroids, and antihistamines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poorly controlled asthma (Asthma Control Test ≤19).&#xD;
&#xD;
          -  Self-reported sleep disturbance on 2 or more nights in the past 7 days due to allergic&#xD;
             rhinitis.&#xD;
&#xD;
          -  Use of concomitant medication that causes scratching.&#xD;
&#xD;
          -  Major medical condition (such as cancer).&#xD;
&#xD;
          -  Active condition that could affect sleep, such as obstructive sleep apnea, restless&#xD;
             leg syndrome, insomnia, narcolepsy, severe sleep disordered breathing, severe&#xD;
             depression, COVID-19, or hives (urticaria).&#xD;
&#xD;
          -  Having applied topical steroids within 7 days of first or second PSG (important for&#xD;
             biomarkers assessment).&#xD;
&#xD;
          -  Use of systemic immunosuppressant within 30 days of first PSG.&#xD;
&#xD;
          -  Having showered or used moisturizers within 12 hours of first or second PSG.&#xD;
&#xD;
          -  Unable to communicate in English (some PROMIS questionnaires not available in&#xD;
             translation).&#xD;
&#xD;
          -  Other contraindication to receiving dupilumab (such as history of allergic reaction to&#xD;
             dupilumab or any of its components).&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Clinical blindness (circadian disturbing).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna B Fishbein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lurie Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna B Fishbein, MD</last_name>
    <phone>3122276021</phone>
    <email>afishbein@luriechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna B Fishbein, MD</last_name>
      <phone>312-227-6021</phone>
      <email>afishbein@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna B Fishbein, MD</last_name>
      <phone>312-227-6021</phone>
      <email>afishbein@luriechildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

